Captopril
Captopril. First-developed ACE inhibitor — short-acting, sulfhydryl-containing. Faster onset than enalapril (active drug, no prodrug) supports use… Oral half-life 2 h.
First-developed ACE inhibitor — short-acting, sulfhydryl-containing. Faster onset than enalapril (active drug, no prodrug) supports use in hypertensive urgency. Sulfhydryl group may contribute to higher rash + dysgeusia (metallic taste) than newer ACEi.
PK: half-life 2 h and F 0.65 are both VERBATIM and stand, and captopril is confirmed not a prodrug, so there is no analyte question. V 56 L is that paper 0.8 L/kg scaled by an invisible 70 kg — it is measured after intravenous dosing, so it is a TRUE volume and pairs safely with a bioavailability, but the weight assumption is now declared. THE REAL CAVEAT IS NOT TISSUE ACE: the cited abstract documents a DISULPHIDE RESERVOIR with cysteine and glutathione giving "a duration of action longer than that predicted by blood concentrations of unchanged captopril", so the plasma curve understates duration. ka 1.4 /h dropped as unstated. A single self-consistent alternative set exists (PMID:7037265: t½ 1.9 h, F 0.62, Vss 0.7 L/kg) but the stored values are the verbatim ones and were kept.
Pharmacokinetics
- Oral — t½ 2 h · F 65% · Vd 56 L
Sources: PMID:3292102, PMID:7037265